Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Mendoza-Ballesteros, Fabian

< Back


Fabian A. Mendoza-Ballesteros, MD

Fabian A. Mendoza-Ballesteros, MD

Contact Dr. Mendoza-Ballesteros

211 South 9th Street
Walnut Towers, Suite 210
Philadelphia, PA 19107

(215) 955-2820
(215) 923-7885 fax

Medical School

Universidad Nacional Mayor de San Marcos, Lima, Peru - 1999


Internal Medicine, Temple University Hospital, Philadelphia, PA


Columbia University Medical Center (NY Presbyterian Hospital), NY

Board Certification

American Board of Internal Medicine (Rheumatology)

Hospital Appointment

Thomas Jefferson University Hospital

Research & Clinical Interests

Dr. Mendoza’s research is focusing on Systemic Sclerosis.


English, Spanish


Most Recent Peer-Reviewed Publications

  1. Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition
  2. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database
  3. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis
  4. Primary osteoporosis in men: an unmet medical need
  5. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy
  6. Abrogation of transforming growth factor-β-induced tissue fibrosis in mice with a global genetic deletion of Nox4
  7. Longitudinal assessment of patient-reported outcome measures in systemic sclerosis patients with gastroesophageal reflux disease - Scleroderma clinical trials consortium
  8. Photoacoustic Oxygenation Quantification in Patients with Raynaud's: First-in-Human Results
  9. Characteristics of chronic itch in systemic sclerosis: A cross-sectional survey
  10. Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis
  11. Stimulation of transforming growth factor-β1-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1 (ET-1): A novel profibrotic effect of ET-1
  12. Role of muscarinic-3 receptor antibody in systemic sclerosis: Correlation with disease duration and effects of IVIG
  13. Severe eosinophilic fasciitis: Comparison of treatment with d-penicillamine plus corticosteroids vs. corticosteroids alone
  14. Treatment of rapidly progressive systemic sclerosis: Current and futures perspectives
  15. Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue from Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
  16. Treatment of systemic sclerosis: Tyrosine kinase inhibitors
  17. Strategies for anti-fibrotic therapies
  18. Systemic sclerosis disease modification clinical trials design: Quo vadis?
  19. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset
  20. Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function
  21. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
  22. Systemic sclerosis mortality in the United States: 1999-2002 Implications for patient care
  23. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature